NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

JUNS

Jupiter Neurosciences Inc

Jul 11 • 04:00PM ET

2.29

Dollar change +0.38
Percentage change 19.90	%

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.10	Insider Own	58.06%	Shs Outstand	33.10M	Perf Week	38.79%
Market Cap	75.81M	Forward P/E	20.82	EPS next Y	0.11	Insider Trans	0.07%	Shs Float	13.88M	Perf Month	136.81%
Enterprise Value	73.31M	PEG	-	EPS next Q	-0.07	Inst Own	1.14%	Short Float	1.25%	Perf Quarter	308.78%
Income	-3.33M	P/S	-	EPS this Y	-212.50%	Inst Trans	0.37%	Short Ratio	0.40	Perf Half Y	-73.53%
Sales	0.00M	P/B	24.74	EPS next Y	144.00%	ROA	-131.28%	Short Interest	0.17M	Perf YTD	-78.60%
Book/sh	0.09	P/C	27.97	EPS next 5Y	-	ROE	-	52W High	19.51 -88.26%	Perf Year	-
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	44.70% 25.26%	ROIC	-108.50%	52W Low	0.51 349.02%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	24.81% 27.42%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	45.63%	Oper. Margin	-	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.91	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	74.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.91	EPS Q/Q	-140.62%	SMA20	78.37%	Beta	-	Target Price	30.00
Payout	-	Debt/Eq	0.07	Sales Q/Q	-	SMA50	140.42%	Rel Volume	3.93	Prev Close	1.91
Employees	4	LT Debt/Eq	0.00	Earnings	May 28	SMA200	-12.14%	Avg Volume	436.32K	Price	2.29
IPO	Dec 03, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	1,716,028	Change	19.90%

Jul-10-25 04:05PM	Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +18.63% +19.90%
Jun-30-25 03:15PM	Jupiter Neurosciences Showcases Nugevia PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery (GlobeNewswire)
Jun-27-25 08:00AM	Jupiter Neurosciences Unveils Nugevia GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science (GlobeNewswire)
Jun-23-25 08:00AM	Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia Brand Ambassador (GlobeNewswire) +8.11%
08:00AM	Jupiter Neurosciences Names Golf Legend Annika Sorenstam as First Nugevia Brand Ambassador (GlobeNewswire)
07:00AM	Loading…
Jun-09-25 07:00AM	Jupiter Neurosciences Launches Nugevia: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science (GlobeNewswire) +15.20%
Apr-08-25 08:00AM	Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter (GlobeNewswire)
Mar-07-25 10:10AM	Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Mar-04-25 08:00AM	Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products (GlobeNewswire) +6.14%
Feb-04-25 09:25AM	Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones (GlobeNewswire) +11.36%
Feb-03-25 08:00AM	Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial (GlobeNewswire) -5.84%
Jan-30-25 08:00AM	Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial (GlobeNewswire) -8.20%
Jan-13-25 08:00AM	Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL Trials (GlobeNewswire)
Dec-04-24 04:56PM	Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering (GlobeNewswire) +9.93%
Dec-02-24 07:00PM	Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq (GlobeNewswire)

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The firm offers JOTROL, an enhanced orally administered resveratrol formulation, designed to deliver therapeutically relevant, safe levels of resveratrol. The company was founded by Christer Rosen, Alexander Rosen, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in January 2016 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elmasri Saleem	CFO and Secretary	Jun 02 '25	Option Exercise	0.00	66,293	0	66,239	Jul 07 09:28 PM
Silva Alison D.	Pres + Chief Business Officer	Jul 01 '25	Buy	1.03	750	772	112,777	Jul 03 08:56 PM
ROSEN CHRISTER	CEO and Chairman	Jul 01 '25	Buy	1.02	3,600	3,667	11,078,892	Jul 03 02:53 PM
Silva Alison D.	Pres + Chief Business Officer	Jun 02 '25	Option Exercise	0.00	110,227	0	110,227	Jul 01 07:55 PM
Silva Alison D.	Pres + Chief Business Officer	Jun 30 '25	Buy	1.03	950	978	112,027	Jul 01 07:55 PM
Silva Alison D.	Pres + Chief Business Officer	Jun 27 '25	Buy	1.03	850	877	111,077	Jul 01 07:55 PM
ROSEN CHRISTER	CEO and Chairman	Jun 02 '25	Option Exercise	0.00	973,466	0	11,067,476	Jul 01 07:55 PM
ROSEN CHRISTER	CEO and Chairman	Jun 30 '25	Buy	1.02	7,650	7,810	11,075,292	Jul 01 07:55 PM
ROSEN CHRISTER	CEO and Chairman	Jun 27 '25	Buy	1.06	166	176	11,067,642	Jul 01 07:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JUNS

Jupiter Neurosciences Inc

Upgrade your FINVIZ experience